References

Pathology of Castleman Disease

10.1016/j.hoc.2017.09.004 · 2018 · External reference

Castleman's Disease: A Case Report of the Unicentric Type

10.4103/2278-0513.134505 · 2014 · External reference

International, Evidence‐Based Consensus Diagnostic Criteria for HHV‐8‐Negative/Idiopathic Multicentric Castleman Disease

10.1182/blood-2016-10-746933 · 2017 · External reference

Validated International Definition of the Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, Renal Insufficiency, and Organomegaly Clinical Subtype (TAFRO) of Idiopathic Multicentric Castleman Disease

10.1002/ajh.26292 · 2021 · External reference

Distinct Interleukin‐6 Production in IPL and TAFRO Subtypes of Idiopathic Multicentric Castleman Disease

2026 · External reference

Characterizing the Heterogeneity of Castleman Disease and Oligocentric Subtype: Findings From the ACCELERATE Registry

10.1182/bloodadvances.2024014391 · 2025 · External reference

Idiopathic Multicentric Castleman Disease (iMCD)‐Idiopathic Plasmacytic Lymphadenopathy: A Distinct Subtype of iMCD‐Not Otherwise Specified With Different Clinical Features and Better Survival

10.1111/bjh.19334 · 2024 · External reference

Overview of Castleman Disease

10.1182/blood.2019000931 · 2020 · External reference

Clinicopathologic Analysis of TAFRO Syndrome Demonstrates a Distinct Subtype of HHV‐8‐Negative Multicentric Castleman Disease

10.1002/ajh.24242 · 2016 · External reference

Treatment Consistent With Idiopathic Multicentric Castleman Disease Guidelines Is Associated With Improved Outcomes

10.1182/bloodadvances.2023010745 · 2023 · External reference

Characteristics of Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis and Organomegaly Syndrome: A Retrospective Study From a Large Western Cohort

10.1111/bjh.17868 · 2022 · External reference

TAFRO Syndrome as a Cause of Glomerular Microangiopathy: A Case Report and Literature Review

10.1186/s12882-019-1574-9 · 2019 · External reference

Humanized Anti‐Interleukin‐6 Receptor Antibody Treatment of Multicentric Castleman Disease

10.1182/blood-2004-12-4602 · 2005 · External reference

Siltuximab, a Novel Anti‐Interleukin‐6 Monoclonal Antibody, for Castleman's Disease

10.1200/jco.2009.27.2377 · 2010 · External reference

Identifying and Targeting Pathogenic PI3K/AKT/mTOR Signaling in IL‐6‐Blockade‐Refractory Idiopathic Multicentric Castleman Disease

10.1172/jci126091 · 2019 · External reference

Expert Perspective: Diagnosis and Treatment of Castleman Disease

10.1002/art.43269 · 2026 · External reference

Potential Stratification of TAFRO Syndrome by Anti‐SS‐A Antibodies Status and Therapeutic Response to Rituximab

10.1136/rmdopen-2025-006547 · 2026 · External reference

Siltuximab for Multicentric Castleman's Disease: A Randomised, Double‐Blind, Placebo‐Controlled Trial

10.1016/s1470-2045(14)70319-5 · 2014 · External reference

International, Evidence‐Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease

10.1182/blood-2018-07-862334 · 2018 · External reference

Complete Resolution of TAFRO Syndrome (Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis and Organomegaly) After Immunosuppressive Therapies Using Corticosteroids and Cyclosporin A: A Case Report

10.3960/jslrt.53.95 · 2013 · External reference

A Case of TAFRO Syndrome, a Variant of Multicentric Castleman's Disease, Successfully Treated With Corticosteroid and Cyclosporine A

10.1080/14397595.2016.1206243 · 2019 · External reference

Successful Treatment With Tacrolimus in TAFRO Syndrome: Two Case Reports and Literature Review

10.1097/md.0000000000011045 · 2018 · External reference

Unresolved reference

2026 · External reference

Idiopathic Multicentric Castleman Disease and Associated Autoimmune and Autoinflammatory Conditions: Practical Guidance for Diagnosis

10.1093/rheumatology/keac481 · 2023 · External reference

Longitudinal, Natural History Study Reveals the Disease Burden of Idiopathic Multicentric Castleman Disease

10.3324/haematol.2023.283603 · 2024 · External reference